Ezequiel E. Trevino-Cavazos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ezequiel E. Trevino-Cavazos has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Abraham Olvera-Barrios
Departamento de Oftalmología. Facultad de Medicina y Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, México
2 shared publications- Jesus Hernan Gonzalez-Cortes
Department of Ophthalmology, University Hospital and Faculty of Medicine, Autonomous University of Nuevo Leon
2 shared publications - Jesús Mohamed-Hamsho
Department of Ophthalmology, University Hospital “DR. Jose E. Gonzalez” and Faculty of Medicine, Autonomous University of Nuevo Leon (UANL), Monterrey, Nuevo Leon, Mexico
2 shared publications B.O. Martínez-Gamero
1 shared publication- Edgar Eliezar Cuervo-Lozano
Ophthalmology Department, University Hospital "José Eleuterio Gonzalez" and Faculty of Medicine, the Autonomous University of Nuevo León, Monterrey 64460, Mexico
1 shared publication Hugo A. Trevino‑Rodríguez
Departamento de Oftalmología. Facultad de Medicina y Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, México
1 shared publication
Latest Publications
- 5 February 2019
- Published by Instituto Mexicano del Seguro Social in Cirugía y Cirujanos
- Vol. 87 (2) , 224-229
Long-term visual and anatomic outcomes after photodynamic therapy for symptomatic circumscribed choroidal hemangioma
Circumscribed choroidal hemangiomas (CCHs) are relatively rare. We report the response of a symptomatic CCH to photodynamic therapy (PDT). A 70-year-old male presented with blurred vision of the left eye (OS). Best-corrected visual acuity (BCVA) was 20/60 right eye and 20/160 OS. Biomicroscopy revealed bilateral cataracts. Diagnosis of CCH was made fundoscopically for OS and confirmed with optical coherence tomography (OCT). One session of PDT with individualized parameters was administered. After 2 months, anatomical improvement was evidenced with OCT and BCVA was 20/60. After cataract surgery, his BCVA was of 20/25 and remained stable. PDT showed excellent anatomic and visual results after a 2-year follow-up.
- 5 February 2019
- Published by Instituto Mexicano del Seguro Social in Cirugía y Cirujanos
- Vol. 87 (2) , 224-229
Long-term visual and anatomic outcomes after photodynamic therapy for symptomatic circumscribed choroidal hemangioma
Circumscribed choroidal hemangiomas (CCHs) are relatively rare. We report the response of a symptomatic CCH to photodynamic therapy (PDT). A 70-year-old male presented with blurred vision of the left eye (OS). Best-corrected visual acuity (BCVA) was 20/60 right eye and 20/160 OS. Biomicroscopy revealed bilateral cataracts. Diagnosis of CCH was made fundoscopically for OS and confirmed with optical coherence tomography (OCT). One session of PDT with individualized parameters was administered. After 2 months, anatomical improvement was evidenced with OCT and BCVA was 20/60. After cataract surgery, his BCVA was of 20/25 and remained stable. PDT showed excellent anatomic and visual results after a 2-year follow-up.
- Open Access
- 18 June 2018
- Published by Press of International Journal of Ophthalmology (IJO Press) in International Journal of Ophthalmology
- Vol. 11 (6) , 981-985
Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema
AIM: To compare the effectiveness of intravitreal bevacizumab and subthreshold macular photocoagulation (SMP), for the treatment of non-center involved diabetic macular edema (non-CI DME). METHODS: Prospective, randomized, controlled clinical study included patients with type 2 diabetes, non-CI DME and best-corrected visual acuity (BCVA) of 0.30 logMAR or better. Each eye was randomized into three groups: group 1, monthly intravitreal bevacizumab; group 2, single SMP; group 3, single SMP and monthly bevacizumab. Main outcome measures were BCVA, and macular thickness measured with optical coherence tomography as macular central subfield thickness (CST), macular area of greater thickness (MAGT) and total macular volume (TMV). Results were analyzed after 3mo. RESULTS: A total of 32 eyes were included. Group 3 improved in BCVA (0.19 +/- 0.16 to 0.12 +/- 0.14 logMAR; P=0.041) and in TMV (7.90 +/- 0.57 to 7.65 +/- 0.73 mm3; P=0.025). Group 1 improved in MAGT (325 +/- 26.26 to 298.20 +/- 44.85 mu m; P=0.022) and TMV (7.79 +/- 0.57 to 7.50 +/- 0.56 mm3, P=0.047). Group 2 didn't show significant improvement of any variable. CONCLUSION: The loading phase of bevacizumab as monotherapy or combined with SMP is superior to SMP as monotherapy in providing short-term visual and anatomical improvement in non-CI DME.
- 18 June 2018
- Published by Press of International Journal of Ophthalmology (IJO Press) in International Journal of Ophthalmology
- Vol. 11 (6) , 981-985
Open AccessShort-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema
AIM: To compare the effectiveness of intravitreal bevacizumab and subthreshold macular photocoagulation (SMP), for the treatment of non-center involved diabetic macular edema (non-CI DME). METHODS: Prospective, randomized, controlled clinical study included patients with type 2 diabetes, non-CI DME and best-corrected visual acuity (BCVA) of 0.30 logMAR or better. Each eye was randomized into three groups: group 1, monthly intravitreal bevacizumab; group 2, single SMP; group 3, single SMP and monthly bevacizumab. Main outcome measures were BCVA, and macular thickness measured with optical coherence tomography as macular central subfield thickness (CST), macular area of greater thickness (MAGT) and total macular volume (TMV). Results were analyzed after 3mo. RESULTS: A total of 32 eyes were included. Group 3 improved in BCVA (0.19 +/- 0.16 to 0.12 +/- 0.14 logMAR; P=0.041) and in TMV (7.90 +/- 0.57 to 7.65 +/- 0.73 mm3; P=0.025). Group 1 improved in MAGT (325 +/- 26.26 to 298.20 +/- 44.85 mu m; P=0.022) and TMV (7.79 +/- 0.57 to 7.50 +/- 0.56 mm3, P=0.047). Group 2 didn't show significant improvement of any variable. CONCLUSION: The loading phase of bevacizumab as monotherapy or combined with SMP is superior to SMP as monotherapy in providing short-term visual and anatomical improvement in non-CI DME.
- Open Access
- 1 July 2015
- Published by Elsevier in Medicina Universitaria
- Vol. 17 (68) , 153-157
Combined therapy in diabetic macular edema
- 1 July 2015
- Published by Elsevier in Medicina Universitaria
- Vol. 17 (68) , 153-157
Open AccessCombined therapy in diabetic macular edema
- 1 December 1983
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 183 (12) , 511-514
Glaskörperfluorophotometrie nach oraler Farbstoffapplikation. I. Neue Version eines Glaskörperfluorophotometers
A new type of vitreous fluorophotometer using a Haag-Streit 900 slitlamp is described. It offers a number of technical and operational advantages. In the photometric part, only commercially available components are used. The system has a custom-designed position indicator. A brief technical description of the calibration of the instrument is given.
- 1 December 1983
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 183 (12) , 511-514
Glaskörperfluorophotometrie nach oraler Farbstoffapplikation. I. Neue Version eines Glaskörperfluorophotometers
A new type of vitreous fluorophotometer using a Haag-Streit 900 slitlamp is described. It offers a number of technical and operational advantages. In the photometric part, only commercially available components are used. The system has a custom-designed position indicator. A brief technical description of the calibration of the instrument is given.